Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 3 studies.
Eur J Haematol
; 109(3): 205-214, 2022 Sep.
Article
in En
| MEDLINE
| ID: mdl-35502600
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Hemoglobinuria, Paroxysmal
Type of study:
Diagnostic_studies
Limits:
Humans
Language:
En
Journal:
Eur J Haematol
Journal subject:
HEMATOLOGIA
Year:
2022
Type:
Article
Affiliation country:
United kingdom